These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 17077659)

  • 1. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
    Rao SN; Rao RD
    Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE; Perry HD
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
    Kurt RA; Yalçindag N; Atilla H; Arat M
    Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-wear silicone hydrogel soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus-host disease.
    Russo PA; Bouchard CS; Galasso JM
    Eye Contact Lens; 2007 May; 33(3):144-7. PubMed ID: 17502749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
    Kujawa A; Rózycki R
    Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
    Malta JB; Soong HK; Shtein RM; Musch DC; Rhoades W; Sugar A; Mian SI
    Cornea; 2010 Dec; 29(12):1392-6. PubMed ID: 20847658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation.
    Donnenfeld ED; Solomon R; Roberts CW; Wittpenn JR; McDonald MB; Perry HD
    J Cataract Refract Surg; 2010 Jul; 36(7):1095-100. PubMed ID: 20610085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
    Roberts CW; Carniglia PE; Brazzo BG
    Cornea; 2007 Aug; 26(7):805-9. PubMed ID: 17667613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.
    Ogawa Y; Okamoto S; Mori T; Yamada M; Mashima Y; Watanabe R; Kuwana M; Tsubota K; Ikeda Y; Oguchi Y
    Bone Marrow Transplant; 2003 Apr; 31(7):579-83. PubMed ID: 12692625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry-eye syndrome after allogeneic stem-cell transplantation in children.
    Fahnehjelm KT; Törnquist AL; Winiarski J
    Acta Ophthalmol; 2008 May; 86(3):253-8. PubMed ID: 18093259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ophthalmic cyclosporine use in ocular GVHD.
    Lelli GJ; Musch DC; Gupta A; Farjo QA; Nairus TM; Mian SI
    Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
    Kim EC; Choi JS; Joo CK
    Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.